## Torrent Pharmaceuticals Limited (TORNTPHARM) Investment Report - December 20, 2024

**1. Company Overview:**

Torrent Pharmaceuticals Limited (TORNTPHARM) is a pharmaceutical company listed on the National Stock Exchange of India (NSE) on November 25, 2002.  It operates within the Pharmaceuticals industry and holds a significant position in the Indian pharmaceutical market, known for its diverse product portfolio and presence in both domestic and international markets.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹3,439.95       | Closed at ₹3,437; slightly higher than the closing price.           |
| Percentage Change (PChange) | -0.84%          | Negative daily change, indicating a slight downward trend.          |
| Pre-Open Activity          | ₹3,476.25       | Higher than the previous close, suggesting potential upward pressure.|
| Week High                    | ₹3,590.7        | High point reached during the week.                                  |
| Week Low                     | ₹2,113.8        | Low point reached during the week, indicating significant volatility.|
| VWAP                        | ₹3,476.61       | Volume Weighted Average Price for the day.                           |
| Sector PE                   | 67.92           | Sector Price-to-Earnings ratio.                                     |
| Symbol PE                   | 65.16           | Company's Price-to-Earnings ratio.                                  |
| Delivery Percentage         | 49.21%          | Relatively high delivery percentage, suggesting some genuine buying.|
| Market Depth                | Low              |  Pre-open order book shows limited depth (low buy and sell quantities).|


**3. Financial Performance:**

The following table summarizes Torrent Pharmaceuticals' financial performance over the past five quarters.  Note that the data shows a consistent profit after tax, but the income and expenditure figures suggest a relatively flat growth pattern.

| Quarter      | Income (₹) | Expenditure (₹) | Profit After Tax (₹) | Diluted EPS (₹) |
|--------------|-------------|-------------------|-----------------------|-----------------|
| Q2 FY25 (Sep 24)| 242,700     | 175,700           | 46,000                | 13.6             |
| Q1 FY25 (Jun 24)| 245,900     | 179,200           | 46,900                | 13.86            |
| Q4 FY24 (Mar 24)| 221,900     | 168,900           | 41,000                | 12.12            |
| Q3 FY24 (Dec 23)| 211,200     | 168,200           | 29,700                | 8.78             |
| Q2 FY24 (Sep 23)| 216,100     | 167,900           | 32,700                | 9.65             |


**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.  The provided data only allows for a limited assessment.


**4. Corporate Actions and Announcements:**

Torrent Pharmaceuticals has a history of consistent dividend payouts and has announced bonus issues in the past.  Recent announcements include updates, press releases, and actions related to share certificates.  The most recent dividend ex-date was June 21, 2024 (₹6 per share).  The consistent dividend payouts are a positive sign.


**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 31-Dec-2023  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 31-Mar-2024  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 30-Jun-2024  | 71.25                        | 28.75      | 0.00                           | 100.00    |
| 30-Sep-2024  | 71.25                        | 28.75      | 0.00                           | 100.00    |

Promoter holding remains stable over the past year, indicating strong management confidence.


**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low prices.  The CM Annual Volatility of 28.28% further confirms this.  This high volatility presents both opportunities and risks.  Investors with a higher risk tolerance might consider this stock, while risk-averse investors should proceed with caution.


**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Stable promoter holding.
* Established presence in the pharmaceutical sector.


**8. Disadvantages and Risks:**

* High volatility.
* Relatively flat revenue growth in recent quarters.
* Dependence on the pharmaceutical market, susceptible to regulatory changes and competition.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price decline and low market depth suggest caution.  Waiting for clearer price momentum is advisable.

* **Medium-term (3 to 12 months): Hold.**  The consistent dividend payouts and stable promoter holding offer some support. However, further monitoring of financial performance is necessary.

* **Long-term (1 year and beyond): Hold.**  Torrent Pharmaceuticals' established position in the pharmaceutical sector provides a long-term growth potential.  However, the company needs to demonstrate stronger revenue growth to justify a "Buy" recommendation.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health (out of 10): 6 (Consistent profitability, but flat revenue growth is a concern).
* Market Performance (out of 10): 5 (High volatility, recent price decline).
* Volatility and Risk (out of 10): 4 (High volatility is a significant risk).
* Corporate Actions & Governance (out of 10): 8 (Consistent dividend payouts and stable promoter holding).
* Shareholding Patterns (out of 10): 9 (Stable promoter holding).


**Analysis Score (out of 10): 9**

* Completeness and Data Utilization (out of 10): 10 (All provided data was used).
* Accuracy and Clarity (out of 10): 9 (Analysis is clear and well-structured).
* Professional Formatting (out of 10): 9 (Report is well-formatted and easy to read).


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, the recommendation for Torrent Pharmaceuticals Limited (TORNTPHARM) is a "Hold" across all investment horizons. While the company demonstrates some strengths, such as consistent dividend payouts and stable promoter holding, the high volatility and relatively flat revenue growth warrant a cautious approach.  Further monitoring of financial performance and market trends is crucial before considering a "Buy" recommendation.  Investors should carefully assess their risk tolerance before investing in this stock.
